Sapient Capital LLC Decreases Stake in Abbott Laboratories $ABT

Sapient Capital LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 37.3% during the first quarter, Holdings Channel reports. The fund owned 17,435 shares of the healthcare product maker’s stock after selling 10,350 shares during the quarter. Sapient Capital LLC’s holdings in Abbott Laboratories were worth $1,790,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Nia Impact Advisors LLC grew its stake in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Clayton Financial Group LLC raised its position in shares of Abbott Laboratories by 1.4% in the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after purchasing an additional 84 shares in the last quarter. Raleigh Capital Management Inc. boosted its stake in shares of Abbott Laboratories by 3.9% during the 4th quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock valued at $287,000 after buying an additional 85 shares during the last quarter. Riggs Asset Managment Co. Inc. boosted its stake in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 88 shares during the last quarter. Finally, GHP Investment Advisors Inc. grew its position in shares of Abbott Laboratories by 0.3% during the fourth quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock worth $3,685,000 after buying an additional 92 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of several recent analyst reports. Oppenheimer cut their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. UBS Group dropped their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Citigroup increased their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $118.17.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $107.16 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a fifty day moving average price of $93.84 and a two-hundred day moving average price of $100.33. The company has a market cap of $185.43 billion, a PE ratio of 34.68, a P/E/G ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company earned $1.26 earnings per share. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.